BIO Elects Dr. Jeremy Levin as New Board Chair

A new slate of officers and Board members were elected during the 2019 BIO International Convention

Time for Congress to Bring Certainty to Biofuels Industry

The Biotechnology Innovation Organization (BIO) today expressed support for a U.S. House of Representatives letter, authored by Representatives Abby Finkenauer (D-Iowa) and Josh Harder (D-Calif.) and signed by 17 additional members, urging Speaker Nancy Pelosi (D-Calif.) and House Ways and Means Committee Chairman Richard Neal (D-Mass.) to extend—and retroactively apply—the expired Second-Generation Biofuel Producer Tax Credit, the Special Depreciation Allowance for Second-Generation Biofuel Plant Property, and the Alternative Fuel Vehicle Refueling Property Credit.

New Direction for Communications and Public Affairs for BIO

BIO announces the hiring of Rich Masters as BIO's new Executive Vice President (EVP) for Public Affairs. Rich officially will join BIO on June 17th. 

BIO Releases 5th Annual Emerging Therapeutic Company Trend Report Showing Record Year for Venture Capital Funding

Washington, D.C. (May 31, 2019) – Today, the Biotechnology Innovation Organization (BIO) released the 2019 Emerging Therapeutic Company Trend Report, highlighting ten years (2009-2018) of biotechnology funding and deal making across five areas: venture capital, Initial Public Offerings (IPOs), follow-on public offerings, licensing, and acquisitions. The report also contains a 2019 snapshot of the industry’s clinical pipeline to highlight the significant contribution of emerging companies.

Year-Round Use of 15 Percent Biofuels in Gasoline Will Reduce Pollution and Save Americans Billions of Dollars

The Biotechnology Innovation Organization (BIO) today released the following statement after the U.S. Environmental Protection Agency (EPA) finalized its rule allowing for the year-round use E15 gasoline.

BIO Honors Dr. Emil D. Kakkis with 2019 Henri A. Termeer Biotechnology Visionary Award

BIO announces the winner of this year’s Henri A. Termeer Biotechnology Visionary Award: Emil D. Kakkis, MD, PhD, President and Chief Executive Officer, Ultragenyx (NASDAQ: RARE) and Founder, EveryLife Foundation for Rare Diseases. The award, which will be presented to Dr. Kakkis on June 5 during the BIO 2019 International Convention keynote session, recognizes Dr. Kakkis’ transformative work to accelerate research and development of novel treatments for rare diseases.

Rare Diseases: BIO Comments on FDA Draft Guidance Rare Diseases: Natural History Studies for Drug Development

BIO appreciates the Agency’s work to develop a much-needed guidance on natural history studies for rare disease drug development. The Draft Guidance serves as an important communication tool between the FDA and Sponsors on issues pertaining to natural history studies for rare disease drug development. Such guidance ensures that Sponsors have appropriate information for developing new therapies for rare disease patients, especially given that many rare diseases still do not have an FDA approved treatment. In the following pages of this letter, BIO has included general comments as well as line edits that we believe will make the Draft Guidance more useful for various stakeholders.

Former U.S. Secretary of Agriculture and Iowa Governor to Receive 2019 George Washington Carver Award

The Biotechnology Innovation Organization (BIO) today announced that former U.S. Department of Agriculture (USDA) Secretary and former two-term Governor of Iowa Tom Vilsack will receive the 12th annual George Washington Carver Award for Innovation in Industrial Biotechnology. 

BIO Applauds Senate Passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act

Legislation will strengthen pipeline of medical countermeasures against serious public health threats

New BIO Report: More Progress Needed in Innovation of Alzheimer’s Disease Therapeutics

Today, the Biotechnology Innovation Organization (BIO) released a new report, The State of Innovation in Highly Prevalent Chronic Diseases Volume IV: Alzheimer’s Disease Therapeutics, the fourth in a series on the innovation landscape of highly prevalent, chronic diseases. This volume takes an in-depth look at the state of innovation for therapeutics in Alzheimer’s disease, which is expected to affect more than 13.8 million people in the United States by 2050 and cost well over $1 trillion annually.